These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32210140)

  • 1. Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma.
    Pant K; Peixoto E; Richard S; Gradilone SA
    Cells; 2020 Mar; 9(3):. PubMed ID: 32210140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and importance of histone modification enzymes in targeted therapy for hepatobiliary cancers.
    Fu W; Gao L; Huang C; Yao J; Lin Y; Bai B; Yue P; Liu Y; Meng W; Qiao L; Li X
    Discov Med; 2019 Jul; 28(151):17-28. PubMed ID: 31465722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma.
    Mastoraki A; Schizas D; Charalampakis N; Naar L; Ioannidi M; Tsilimigras D; Sotiropoulou M; Moris D; Vassiliu P; Felekouras E
    Mol Diagn Ther; 2020 Apr; 24(2):175-184. PubMed ID: 32125662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma - cell line findings.
    Sriraksa R; Limpaiboon T
    Asian Pac J Cancer Prev; 2013; 14(4):2503-8. PubMed ID: 23725164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
    He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
    Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylases: salesmen and customers in the post-translational modification market.
    Brandl A; Heinzel T; Krämer OH
    Biol Cell; 2009 Apr; 101(4):193-205. PubMed ID: 19207105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment.
    Schizas D; Mastoraki A; Naar L; Spartalis E; Tsilimigras DI; Karachaliou GS; Bagias G; Moris D
    World J Gastroenterol; 2018 Nov; 24(41):4635-4642. PubMed ID: 30416311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.
    Zhang M; Pan Y; Tang D; Dorfman RG; Xu L; Zhou Q; Zhou L; Wang Y; Li Y; Yin Y; Kong B; Friess H; Zhao S; Wu JL; Wang L; Zou X
    Cell Commun Signal; 2019 Mar; 17(1):23. PubMed ID: 30866966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in class IIa histone deacetylases research.
    Asfaha Y; Schrenk C; Alves Avelar LA; Hamacher A; Pflieger M; Kassack MU; Kurz T
    Bioorg Med Chem; 2019 Nov; 27(22):115087. PubMed ID: 31561937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis.
    Kim HS; Shen Q; Nam SW
    J Korean Med Sci; 2015 Oct; 30(10):1375-80. PubMed ID: 26425032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role.
    Schizas D; Mastoraki A; Naar L; Tsilimigras DI; Katsaros I; Fragkiadaki V; Karachaliou GS; Arkadopoulos N; Liakakos T; Moris D
    Curr Med Chem; 2020; 27(36):6099-6111. PubMed ID: 31309879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
    Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
    Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional regulation by the acetylation of nonhistone proteins in humans -- a new target for therapeutics.
    Das C; Kundu TK
    IUBMB Life; 2005 Mar; 57(3):137-49. PubMed ID: 16036576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
    Ganai SA
    Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone acetylation: plants and fungi as model systems for the investigation of histone deacetylases.
    Graessle S; Loidl P; Brosch G
    Cell Mol Life Sci; 2001 May; 58(5-6):704-20. PubMed ID: 11437232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linking epigenetics to lipid metabolism: focus on histone deacetylases.
    Ferrari A; Fiorino E; Giudici M; Gilardi F; Galmozzi A; Mitro N; Cermenati G; Godio C; Caruso D; De Fabiani E; Crestani M
    Mol Membr Biol; 2012 Nov; 29(7):257-66. PubMed ID: 23095054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
    Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
    Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.